Tuesday, May 24, 2016 8:45:02 PM
$NEOT, 1.18 steady accumulation, chart & catalyst:
Plans to begin a new P2 trial during 3Q16 evaluating modified formulation w/ topline data expected during 1Q17. Plans to begin P2 proof of concept trial during 3Q16 to reduce fat deposits under chin (submental fat) w/ topline data expected by YE16, being developed as novel injected formulation of drug approved in several inhaled products (e.g. ADVAIR)
[/img]
Plans to begin a new P2 trial during 3Q16 evaluating modified formulation w/ topline data expected during 1Q17. Plans to begin P2 proof of concept trial during 3Q16 to reduce fat deposits under chin (submental fat) w/ topline data expected by YE16, being developed as novel injected formulation of drug approved in several inhaled products (e.g. ADVAIR)
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
